DDInter462 DDInter1747
Dabrafenib mesylate (Tafinlar) is a reversible ATP-competitive kinase inhibitor and targets the MAPK pathway. It was approved on May 29, 2013, for the treatment of melanoma with V600E or V6000K mutation. It was also used for metastatic non-small cell lung cancer with the same mutation. In May 2018, Tafinlar (dabrafenib), in combination with Mekinist (), was approved to treat anaplastic thyroid cancer caused by an abnormal BRAF V600E gene.
Tasimelteon is a selective dual melatonin receptor agonist indicated for the treatment of Non-24-Hour Sleep-Wake Disorder (N24HSWD). Occurring commonly in blind individuals without light perception, this condition is often characterized by periods of night-time insomnia and day-time sleepiness. In blind individuals, a lack of light stimulation causes an extension of the 24-hour circadian cycle and can lead to progressively delayed sleep onset. By activating melatonin receptors MT1 and MT2 in the suprachiasmatic nucleus of the brain, tasimelteon has been shown to improve sleep by resynchronizing the circadian rhythm through its "non-photic" mechanism. Tasimelteon is currently the only drug available for the treatment of N24HSWD and was granted orphan drug status by the FDA in 2010.
Dabrafenib {u} (Compound) binds {v} (Gene) SLCO1B3
Dabrafenib {u} (Compound) upregulates {v} (Gene) PSAT1
Dabrafenib {u} (Compound) is included by {v} (Pharmacologic Class) Organic Anion Transporter 3 Inhibitors
Dabrafenib {u} (Compound) downregulates {v} (Gene) LIG1
Dabrafenib {u} (Compound) causes {v} (Side Effect) Abdominal pain
Dabrafenib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Bortezomib
Dabrafenib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Fostemsavir
Dabrafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nilotinib
Dabrafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Darolutamide
Dabrafenib {u} may lead to a major life threatening interaction when taken with {v} Levacetylmethadol
Dabrafenib (Compound) binds SLCO1B3 (Gene)
Dabrafenib (Compound) upregulates PSAT1 (Gene)
Dabrafenib (Compound) is included by Organic Anion Transporter 3 Inhibitors (Pharmacologic Class)
Dabrafenib (Compound) downregulates LIG1 (Gene)
Dabrafenib (Compound) causes Abdominal pain (Side Effect)
Dabrafenib may cause a minor interaction that can limit clinical effects when taken with Bortezomib
Dabrafenib may cause a minor interaction that can limit clinical effects when taken with Fostemsavir
Dabrafenib may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib
Dabrafenib may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide
Dabrafenib may lead to a major life threatening interaction when taken with Levacetylmethadol